What is prothrombin time (PT) and its significance in unfractionated heparin infusion?

Prothrombin Time (PT) is NOT Used to Monitor Heparin Infusion

Prothrombin time (PT) and its derivative INR are NOT appropriate tests for monitoring unfractionated heparin (UFH) therapy. The activated partial thromboplastin time (aPTT) or anti-Xa assay are the correct monitoring tests for heparin infusion 1, 2.

What is Prothrombin Time?

PT measures the time it takes for blood to clot through the extrinsic and common coagulation pathways. It was originally designed and validated specifically for monitoring vitamin K antagonists (VKA) like warfarin, not heparin 3. The PT is expressed as:

• Seconds (raw clotting time)
• PT ratio (patient PT/control PT)
• INR (International Normalized Ratio) - standardized for warfarin monitoring only
• Activity percentages

Why PT is Irrelevant for Heparin Monitoring

The PT/INR was never designed, validated, or intended for heparin monitoring 3. Here's why:

Mechanism Mismatch

• Heparin works by binding to antithrombin III to inhibit factors Xa and IIa (thrombin), primarily affecting the intrinsic pathway 2
• PT measures the extrinsic pathway (tissue factor pathway), which heparin affects minimally 1
• PT may be slightly prolonged by heparin, but this prolongation is inconsistent, unpredictable, and clinically meaningless 2, 4, 5

Evidence Against PT for Heparin

The FDA drug label explicitly states: "Heparin sodium may prolong the one-stage prothrombin time" but provides no guidance to use PT for monitoring - because it shouldn't be used 2. Studies show PT changes with heparin are variable and do not correlate with therapeutic anticoagulation 5.

Correct Monitoring for Heparin Infusion

Standard Approach: aPTT

The aPTT is the traditional test for UFH monitoring 1, 6, 7:

• Target aPTT ratio: 1.5-2.5 times control (corresponds to heparin levels of 0.3-0.7 U/mL by anti-Xa assay) 1, 6
• Check aPTT 6 hours after bolus dose and adjust infusion accordingly 7
• Use weight-based dosing nomograms: 80 U/kg bolus, then 18 U/kg/hour infusion 6, 7

Critical caveat: The therapeutic aPTT range varies significantly between reagents and coagulometers 1. Each institution must establish its local therapeutic range by correlating aPTT ratios with anti-Xa levels of 0.3-0.7 U/mL 1.

Preferred Approach: Anti-Xa Assay

Anti-Xa assay is increasingly preferred over aPTT, especially in critically ill patients 8, 9, 10:

• Target anti-Xa level: 0.3-0.7 U/mL for therapeutic anticoagulation 1, 9
• Less affected by pre-analytical variables and laboratory interference 8
• Not influenced by elevated acute phase reactants (factor VIII, fibrinogen) that cause "heparin resistance" 8

In hyperinflammatory states (COVID-19, critical illness), aPTT becomes unreliable - it may normalize despite adequate heparin levels, potentially leading to dangerous overdosing if clinicians increase heparin based on "low" aPTT 8. In these patients, anti-Xa monitoring is strongly recommended 8.

Special Monitoring Considerations

Parameters to Monitor (NOT PT)

When patients are on heparin infusion, monitor 8:

• Platelet count: Check every 24-72 hours in critically ill patients, or 1-2 times weekly in stable patients to detect heparin-induced thrombocytopenia (HIT) 8
• Fibrinogen level: High fibrinogen (acute phase reactant) can cause heparin resistance; low fibrinogen may indicate DIC or risk of heparin overdose 8
• PT/INR only if: Patient is also on warfarin for transition therapy 2, 4

Timing When Transitioning to Warfarin

If a patient receives both heparin and warfarin simultaneously (common practice for VTE treatment), PT/INR will be artificially prolonged by heparin 2, 4:

• Wait 5 hours after stopping IV heparin or 24 hours after stopping subcutaneous heparin before drawing PT/INR to assess warfarin effect alone 2
• The PT decrease after stopping heparin is unpredictable (can drop 0.8-5.5 seconds) 4
• Repeat PT/INR after stopping heparin before making warfarin dosing decisions 4

Common Pitfalls to Avoid

1. Never use PT/INR to monitor heparin therapy - it lacks validity, sensitivity, and clinical correlation 3
2. Don't assume a single aPTT therapeutic range applies universally - validate your local range against anti-Xa levels 1
3. In critically ill/inflammatory states, don't rely solely on aPTT - use anti-Xa assay to avoid heparin overdosing 8
4. Don't forget to monitor platelets - HIT can occur and is life-threatening 8, 6
5. When overlapping heparin and warfarin, wait appropriate time after stopping heparin before using PT/INR for warfarin dosing 2, 4